These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31255385)

  • 1. Switching Antiretroviral Therapy in the Setting of Virologic Suppression: A Why and How-To Guide.
    Wood BR
    Infect Dis Clin North Am; 2019 Sep; 33(3):693-705. PubMed ID: 31255385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ready for HIV Dual Therapy? - New Data from International HIV/AIDS Society 2017.
    Yendewa GA; Salata RA
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?
    Moreno S; Perno CF; Mallon PW; Behrens G; Corbeau P; Routy JP; Darcis G
    HIV Med; 2019 Apr; 20 Suppl 4():2-12. PubMed ID: 30821898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy.
    Chastain D; Badowski M; Huesgen E; Pandit NS; Pallotta A; Michienzi S
    J Int Assoc Provid AIDS Care; 2019; 18():2325958219867325. PubMed ID: 31516088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies.
    Patten G; Schomaker M; Davies MA; Rabie H; van Zyl G; Technau K; Eley B; Boulle A; Van Dyke RB; Patel K; Sipambo N; Wood R; Tanser F; Giddy J; Cotton M; Nuttall J; Essack G; Karalius B; Seage G; Sawry S; Egger M; Fairlie L;
    Pediatr Infect Dis J; 2019 Apr; 38(4):400-405. PubMed ID: 30882732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
    Ribera E
    AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Virologic Failure and HIV Drug Resistance.
    McCluskey SM; Siedner MJ; Marconi VC
    Infect Dis Clin North Am; 2019 Sep; 33(3):707-742. PubMed ID: 31255384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants.
    Shiau S; Strehlau R; Technau KG; Patel F; Arpadi SM; Coovadia A; Abrams EJ; Kuhn L
    AIDS; 2017 Jan; 31(3):355-364. PubMed ID: 27828785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations.
    Laut KG; Shepherd L; Gottfredsson M; Sedlacek D; Knysz B; Begovac J; Radoi R; Schmied B; Chkhartishvili N; Florence E; Ristola M; Fätkenheuer G; Mulcahy F; Schmid P; Kuzovatova E; Paduta D; Smidt J; Domingo P; Szlávik J; Lundgren J; Mocroft A; Kirk O;
    AIDS; 2018 Nov; 32(18):2807-2819. PubMed ID: 30289816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Antiretroviral Therapy Use and Virologic Suppression in the Bronx in the Context of Multiple HIV Prevention Strategies.
    Hanna DB; Felsen UR; Ginsberg MS; Zingman BS; Beil RS; Futterman DC; Strickler HD; Anastos K
    AIDS Res Hum Retroviruses; 2016; 32(10-11):955-963. PubMed ID: 26892622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era.
    Roul H; Mary-Krause M; Ghosn J; Delaugerre C; Pialoux G; Cuzin L; Launay O; Lacombe JM; Menard A; De Truchis P; Delfraissy JF; Weiss L; Costagliola D;
    AIDS; 2018 Nov; 32(17):2605-2614. PubMed ID: 30289817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching Human Immunodeficiency Virus Therapy: Basic Principles and Options.
    Bacic Lima D; Solomon DA
    Infect Dis Clin North Am; 2024 Sep; 38(3):409-422. PubMed ID: 38871570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy: treatment-experienced individuals.
    Calvo KR; Daar ES
    Infect Dis Clin North Am; 2014 Sep; 28(3):439-56. PubMed ID: 25151565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
    Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral Suppression in a Nationwide Sample of HIV-Infected Children on Antiretroviral Therapy in Rwanda.
    Nsanzimana S; McArdle F; Remera E; Mulindabigwi A; Ribakare M; Ndimubanzi P; Kayirangwa E; Baribwira C; Riedel DJ; Ntaganira J
    Pediatr Infect Dis J; 2019 Feb; 38(2):149-151. PubMed ID: 29794653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation.
    Desmonde S; Eboua FT; Malateste K; Dicko F; Ekouévi DK; Ngbeché S; Koueta F; Sy HS; Renner L; Koumakpai SA; Leroy V;
    AIDS; 2015 Jul; 29(12):1527-36. PubMed ID: 26244392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
    Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
    BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.